Currently, inhibitors targeting PRMT3 and CARM1 are actively being developed to inhibit the activity of these enzymes, (as shown in Table 2), thereby disrupting the survival and proliferation of tumour cells. This evidence concerns the gene PRMT3 and neoplasm.